Invention Grant
US09359418B2 Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
有权
抑制T细胞特异性替代p38的活化途径及使用方法
- Patent Title: Inhibitors of the T cell-specific alternative p38 activation pathway and methods of use
- Patent Title (中): 抑制T细胞特异性替代p38的活化途径及使用方法
-
Application No.: US14443278Application Date: 2013-11-19
-
Publication No.: US09359418B2Publication Date: 2016-06-07
- Inventor: Jonathan D. Ashwell , Muhammad S. Alam
- Applicant: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicant Address: US DC Washington
- Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Current Assignee Address: US DC Washington
- Agency: Klarquist Sparkman, LLP
- International Application: PCT/US2013/070813 WO 20131119
- International Announcement: WO2014/081728 WO 20140530
- Main IPC: C07K14/00
- IPC: C07K14/00 ; C07K14/475 ; A61K38/00
Abstract:
In T lymphocytes, p38 mitogen activated protein kinase (MAPK) can be activated through an alternative pathway that involves phosphorylation at tyrosine 323. Disclosed herein is the identification of a minimal region of the growth arrest and DNA damage-inducible alpha (Gadd45α) protein that is required for binding to and inhibition of tyrosine 323-phosphorylated p38 in T cells. The disclosed Gadd45α polypeptides inhibit proliferation of T cells in response to T cell receptor stimulation, inhibit differentiation of T cells into Th1 or Th17 cells, inhibit the production of proinflammatory cytokines, and reduce tumor formation and growth of inflammatory cancers, such as pancreatic cancer.
Public/Granted literature
- US20160083442A1 INHIBITORS OF THE T CELL-SPECIFIC ALTERNATIVE P38 ACTIVATION PATHWAY AND METHODS OF USE Public/Granted day:2016-03-24
Information query
